Table 2 Outcomes of BCMA-targeted CAR-T cell clinical trials in MM
Author | Agent | Clinical Trial Identifier | Patients (n) | Medium number of prior LOT (range) | ISS Stage 3 | High-risk cytogenetics (%) | ORR (%) | ≥ CR (%) | Median PFS (months) | Median OS (months) | Hazard Ratio for Disease Progression or Death | Grade ≥ 3 CRS (%) | Grade ≥ 3 Neurotoxicity (%) | References |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Munshi et al. | Ide-cel | NCT03361748 | 128 | 6 (3–16) | 16.0% | 35.0 | 73.0 | 33.0 | 8.8 | Immature | – | 5.0 | 3.0 | [1] |
Mi et al. | Cilta-cel | NCT03758417 | 48 | 4 (3–9) | 18.8% | 43.8 | 89.6 | 77.1 | Not reached | Not reached | – | 35.4 | 0.0 | [3] |
Mi et al. | LCAR-B38M CAR-T | NCT03090659 | 74 | 3 (1–9) | 28.4% | 35.7 | 87.8 | 73.0 | 18 | 55.8 | – | 9.5 | 0.0 | |
Lin et al. | Cilta-cel | NCT03548207 | 97 | 6 (4–8) | 14.0% | 24.0 | 97.9 | 82.5 | 34.9 | Not reached | – | 5.2 | 12.4 | |
Rodriguez-Otero et al.* | Ide-cel | NCT03651128 | 254 | 3 (2–4) | 12.0% | 42.0 | 71.0 | 39.0 | 13.3 | Immature | 0.49 | 5.0 | 3.0 | [7] |
Dhakal et al.* | cilta-cel | NCT04181827 | 208 | 2 (1–3) | 5.8% | 59.4 | 84.6 | 73.1 | Not reached | Immature | 0.26 | 1.1 | 2.8 | |
Sperling et al. | PHE885 | NCT04318327 | 50 | 4 (2–10) | 54%†| 36.0 | 98.0 | 41.0 | – | – | – | 10.0 | 6.0 | [10] |
Du et al. | GC012F | NCT04236011; NCT04182581 | 29 | 5 (2–9) | – | 90.0 | 93.1 | 82.8 | 38 | – | – | 7.0 | 0.0 | [11] |